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Negative Wet % Sensitivity
N N (Ave. CT Value Wet; Dry) N (Ave. CT Value) N (Ave. CT Value) Wet Swabs Dry Swabs
Immunocompetent Controls (N 5 106
collections)
All virus detections# 28 78 (27.1; 27.2) 10 (34.6) 3 (34.3) 97 89
+ Rhinorrhea (n 5 83)* 18 65 (26.8; 26.8) 7a (35.4) 3b (34.3) 96 91
2 Rhinorrhea (n 5 22)* 9 13 (28.9; 29.4) 3c (32.8) 0 100 81
HCT Patients (N 5 105 collections)
All virus detections# 20 69 (28.2; 28.4) 14 (33.5) 12 (32.8) 87 85
+ Rhinorrhea (n 5 66) 9 48 (27.5; 27.8) 8d (32.5) 7e (33.0) 89 87
2 Rhinorrhea (n 5 39) 11 21 (29.9; 29.7) 6f (35.9) 5g (32.4) 84 81
#Total N is greater than number of paired swab collections because of multiple virus detections in some swabs.
*1 survey was blank for rhinorrhea and omitted. Discordant virus detections.
aAdenovirus (AdV) x3, parainfluenza (PIV) 3, PIV4, coronavirus (HCoV)/rhinovirus (HRV) co-infection.
bHRV x2, bocavirus.
cInfluenza A, AdV, HCoV.
drespiratory syncytial virus (RSV) x2, PIV3 x2, HRV x2, AdV, HCoV.
ePIV3, PIV1, HCoV, HRV x4.
fRSV, PIV3 x2, HCoV x2, AdV.
gRSV x2, HRV x3.
S346 Poster Session IIwere stored at ambient temperature, and PCR testing was performed
for 12 RVs (positive value 5 threshold cycle [CT]\ 40).
Results: Samples were collected during 106 URIs in 70 immuno-
competent persons; 3 subjects were \ 6 yo (parent performed).
Counting all positive respiratory virus detections as true positives,
sensitivity was 88/91 5 97% for wet swabs and 81/91 5 91% for
dry (Table). Among 30 HCT recipients aged . 6 yo, 105 paired
samples were collected during 30 URIs (median 3 samples/patient,
range 1-9). Sensitivity was 83/955 87% for wet swabs and 81/955
85% for dry. In both populations, discordant results were associated
with higher averageCT values (i.e., lower viral load), and discordance
was highest in samples collected fromHCT recipients. Dry swabs, in
particular, appeared to perform better in subjects with rhinorrhea
than without. A subset of 73 immunocompetent subjects rated the
self collected swabs simple (96%) and comfortable (88%); no epi-
staxis occurred with any collection.
Conclusion: Ourmethod of foam swab self-collection of nasal secre-
tions is simple, comfortable, and safe amongHCT recipients. Discor-
dance between wet and dry swabs increased with lower viral load.
Overall, thewet swabappeared to increase sensitivity for respiratory vi-
ral detection in both immunocompetent subjects and HCT patients.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR SICKLE CELL ANEMIA
(SCA) AT MSKCC: A SINGLE INSTITUTION SERIES
Anur, P., Sklar, C., Kernan, N.A., Prockop, S.E., Scaradavou, A.,
Small, T.N., O’Reilly, R.J., Boulad, F. Memorial Sloan Kettering Cancer
Center, New York, NY
Background: Allogeneic hematopoietic stem cell transplantation
(SCT) is the only proven cure for children with sickle cell anemia.
SCT is considered for high risk patients with SCA who have an
HLA-matched sibling donor.
Methods: We reviewed medical records of 13 children (1.4 -19.2
years, 8 females and 5 males) who received allogeneic SCT from
matched sibling donors from 1994-2010 for SCA at Memorial
Sloan-Kettering Cancer Center (MSKCC).
Results: Indications for HSCTwere: stroke (n5 3), acute chest syn-
drome (n 5 6), multiple vaso-occlusive crises (n 5 10), and allo-im-
munization (n 5 3); nine patients had more than one risk factor.
Donors were heterozygous for sickle cell (n5 9) or with normal he-
moglobin (n 5 4). All patients received marrow grafts while one pa-
tient received combined marrow and cord blood grafts. Nine
patients received standard cytoreduction with Busulfan/Cyclophos-
phamide. Three other regimens were used in an attempt to decrease
toxicity and improve chimerism. They were Busulfan/Fludarabine
(n 5 2), Busulfan/Cyclophosphamide/Fludarabine (n 5 1) andBusulfan/Melphalan/Fludarabine (n 5 1). GvHD prophylaxis in-
cluded cyclosporine (CSA) and methotrexate (MTX) (n 5 9), tacro-
limus and MTX (n 5 2), or other (n 5 2). All 13 patients engrafted.
With a median follow-up of 10.2 years (range 0.9-17.6 years), twelve
of 13 patients are alive and well. One patient died of interstitial pneu-
monitis on day +77 post SCT. No patient developed acute GvHD.
Two patients developed de-novo limited chronic GvHD, which re-
solved. Donor chimerism included 100% (n 5 5), 76-97% (n 5 5)
while two patients recipients of Bu/Cy regimen had 35% and 50%
donor cells. Six of 7 evaluable patients showed evidence of splenic
function recovery post transplant. Late effects analysis included eval-
uation of gonadal function revealing 6 of 8 females with ovarian
dysfunction.
Conclusions: This single institution based SCT series for SCA is
consistent with multi-institutional series results, showing a very
good outcome following Busulfan based myeloablative regimen. Fu-
ture directions include the improvement of donor chimerism, and
the late effects of treatment including that of gonadal function.
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FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH
AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY
CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION
Nicholson, E.1, Mackinnon, S.1, Thomson, K.J.2, Sudak, J.1,
Fielding, A.K.1, Kottaridis, P.1, Peggs, K.S.2, Morris, E.C.2,
Chakraverty, R.1 1Royal Free Hospital, London, United Kingdom;
2University College Hospital, London, United Kingdom
For patients with high-risk acute myeloid leukemia(AML),mye-
loablative conditioning(MAC) followed by allogeneic hematopoietic
stem cell transplantation(allo-HSCT) offers the best chance of long-
term disease free survival.Retrospective analysis comparing reduced
intensity conditioning(RIC) and MAC suggest that early OS and
PFS rates are comparable where increased relapse rate(RR) is offset
by reduced non-relapse mortality(NRM).In AML patients receiving
a RIC regimen,very high RR has been observed in patients with poor
risk cytogenetics.We analyzed outcomes of 70 consecutive adult pa-
tients with AML or MDS(CR1 or CR2 at time of allo-HSCT) who
received Fludarabine(150mg/m2),Melphalan(140mg/m2) Alemtu-
zumab(CAMPATH)(20-100mg)(FMC) RIC regimen.Median age
at transplant was 56 yrs(range 17-70).29 had a HLA identical sibling
donor and 41 an unrelated donor(29 matched;12 mismatched).Stem
cell source was PBSC in 66 and BM in 4 patients.43 patients were in
CR1 and 27 were in CR2.Median follow up of live patients was 32
months(range 12-119).OS and PFS at 3 yrs was 55% and
53%.100-day and 3-yr NRM rates were 10% and 24%.3-yr
RR was 25% and median time to relapse was 6.2 months (range
